KR960704911A - 2',5'-올리고아데닐레이트-2',3'- 시클로포스페이트 (2',5'-oligoadenylate-2',3'-cyclophosphates) - Google Patents

2',5'-올리고아데닐레이트-2',3'- 시클로포스페이트 (2',5'-oligoadenylate-2',3'-cyclophosphates)

Info

Publication number
KR960704911A
KR960704911A KR1019960701492A KR19960701492A KR960704911A KR 960704911 A KR960704911 A KR 960704911A KR 1019960701492 A KR1019960701492 A KR 1019960701492A KR 19960701492 A KR19960701492 A KR 19960701492A KR 960704911 A KR960704911 A KR 960704911A
Authority
KR
South Korea
Prior art keywords
oligoadenylate
cyclophosphate
compound
papilloma virus
trauma caused
Prior art date
Application number
KR1019960701492A
Other languages
English (en)
Other versions
KR100332250B1 (ko
Inventor
아이. 부도브스키 에드워드
이. 가브릴로프 알렉산더
디. 피바시얀 아만
Original Assignee
아이. 부도브스키 에드워드
이. 가브릴로프 알렉산더
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이. 부도브스키 에드워드, 이. 가브릴로프 알렉산더 filed Critical 아이. 부도브스키 에드워드
Publication of KR960704911A publication Critical patent/KR960704911A/ko
Application granted granted Critical
Publication of KR100332250B1 publication Critical patent/KR100332250B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

본 발명은 하기 일반식(I)로 표시되는 신규의 2´,5´-올리고아데닐레이트-2´,3´-시클로포스페이트, 이를 활성 성분으로 함유하는 의약, 및 이의 사용방법에 관한 것이다.
상기 식에서, 0≤n≤10, 특히 n≥0 내지 10이고, 바람직하게는 1 또는 2이다.

Description

2´,5´-올리고아데닐레이트-2´,3´-시클로포스페이트(2´,5´-OLIGOADE-NYLATE-2´,3´-CYCLOPHOSPHATES)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 하기 일반식(I)로 표시되는 2´,5´-올리고아데닐레이트-2´,3´-시클로포스페이트 ;
    상기 식에서, 0≤n≤10, 특히 n≥0 내지 10이고, 바람직하게는 1 또는 2이다.
  2. 아데노신-2´(3´)-포스페이트를 불규칙한 3´,5´-및 2´-5´-누클레오티드간 결합을 가진 폴리(A)와 중합시키고, 그 중합체를 B 중간물(EC. 3. 1. 4. 23)로부터 얻은 RN아제로 처리하는 단계를 포함하여, 확인가능한 방식에 의해 구별되는 제1항에서 정의한 화합물을 제조하는 방법.
  3. 유두종 바이러스에 의해 유발된 양성 전암성(precancerous) 피부 및 점막 외상을 치료하기 위한 약학제제로서, 약학적 허용 담체 또는 용매와 함께 활성 성분으로서 제1항에서 정의한 하나 이상의 화합물 또는 혼합물을 함유하는 약학 제제.
  4. 유효량의 제3항에서 정의한 제제 또는 화합물을 국소 도포하는 것을 포함하여 유두종 바이러스에 의해 유발된 피부 및 점막 외상을 국부적으로 치료하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960701492A 1993-09-24 1993-09-24 2',5'-올리고아데닐레이트2',3'-시클로포스페이트 KR100332250B1 (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1993/002596 WO1995008555A1 (de) 1993-09-24 1993-09-24 2',5'-oligoadenylat-2',3'-cyclophosphate

Publications (2)

Publication Number Publication Date
KR960704911A true KR960704911A (ko) 1996-10-09
KR100332250B1 KR100332250B1 (ko) 2002-12-05

Family

ID=8165765

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960701492A KR100332250B1 (ko) 1993-09-24 1993-09-24 2',5'-올리고아데닐레이트2',3'-시클로포스페이트

Country Status (9)

Country Link
US (2) US5739013A (ko)
EP (1) EP0721457B1 (ko)
JP (1) JPH09509647A (ko)
KR (1) KR100332250B1 (ko)
DE (1) DE69324826D1 (ko)
DK (1) DK0721457T3 (ko)
ES (1) ES2133412T3 (ko)
GR (1) GR3030863T3 (ko)
WO (1) WO1995008555A1 (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127446A1 (en) * 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
KR100332250B1 (ko) * 1993-09-24 2002-12-05 이. 가브릴로프 알렉산더 2',5'-올리고아데닐레이트2',3'-시클로포스페이트
US5955446A (en) * 1997-01-16 1999-09-21 Pentose Pharmaceuticals, Inc. Method of treating herpes infections with 2',5'-oligoadenylate-2',3'-cyclophosphate compounds
US7049110B2 (en) * 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US20070099170A1 (en) * 1998-07-21 2007-05-03 Navigant Biotechnologies, Inc. Method for treatment and storage of blood and blood products using endogenous alloxazines and acetate
US6258577B1 (en) 1998-07-21 2001-07-10 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers
US7498156B2 (en) * 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
WO2000061804A1 (en) * 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
AU1494801A (en) * 1999-09-29 2001-04-30 Cleveland Clinic Foundation, The Therapy with 2-5a and interferon
US6268120B1 (en) 1999-10-19 2001-07-31 Gambro, Inc. Isoalloxazine derivatives to neutralize biological contaminants
TW590780B (en) * 2000-06-02 2004-06-11 Gambro Inc Additive solutions containing riboflavin
US7985588B2 (en) * 2000-06-02 2011-07-26 Caridianbct Biotechnologies, Llc Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US7648699B2 (en) * 2000-06-02 2010-01-19 Caridianbct Biotechnologies, Llc Preventing transfusion related complications in a recipient of a blood transfusion
US6843961B2 (en) * 2000-06-15 2005-01-18 Gambro, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US20020123480A1 (en) * 2000-10-24 2002-09-05 Edson Clark M. Methods and compositions utilizing 2'-5' oligoadenylates in the treatment of disorders of cell proliferation
JP2005537028A (ja) * 2002-06-26 2005-12-08 ザ　ペン　ステート　リサーチ　ファウンデーション ヒト乳頭腫ウイルス感染症を治療する方法及び材料
US7134395B2 (en) * 2004-01-20 2006-11-14 Southern Lithoplate, Inc. Acid inkjet imaging of lithographic printing plates
KR20210062430A (ko) 2019-11-21 2021-05-31 대한민국(전북기계공업고등학교장) 동력 전달 장치를 활용한 교육 시스템

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5312891A (en) * 1976-07-23 1978-02-04 Kikkoman Corp Novel 1,n6-etheno-2-substituted-adenosine-3,5-cyclic phosphoric acid
IL58421A (en) * 1979-10-09 1984-01-31 Yeda Res & Dev Production of(2'-5')oligoisoadenylate and pharmaceutical compositions containing it
US5550111A (en) * 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US4859768A (en) * 1984-07-11 1989-08-22 Temple University Of The Commonwealth System Of Higher Education Derivatives of 2', 5'-oligoadenylate and antiviral uses thereof
DE4211238C2 (de) * 1992-04-03 1994-10-27 Edward I Budowskij Verwendung von 2',5'-Oligoadenylaten zur Behandlung von Papillomatosen
KR100332250B1 (ko) * 1993-09-24 2002-12-05 이. 가브릴로프 알렉산더 2',5'-올리고아데닐레이트2',3'-시클로포스페이트

Also Published As

Publication number Publication date
EP0721457B1 (de) 1999-05-06
US5962431A (en) 1999-10-05
DE69324826D1 (de) 1999-06-10
WO1995008555A1 (de) 1995-03-30
ES2133412T3 (es) 1999-09-16
KR100332250B1 (ko) 2002-12-05
GR3030863T3 (en) 1999-11-30
US5739013A (en) 1998-04-14
DK0721457T3 (da) 1999-11-08
EP0721457A1 (de) 1996-07-17
JPH09509647A (ja) 1997-09-30

Similar Documents

Publication Publication Date Title
KR960704911A (ko) 2',5'-올리고아데닐레이트-2',3'- 시클로포스페이트 (2',5'-oligoadenylate-2',3'-cyclophosphates)
KR950013511A (ko) 실금 치료
BR9815570A (pt) Composto, processo de preparação dos compostos, utilização de pelo menos um composto, composição cosmética ou farmacêutica e utilização de pelos menos um polìmero
KR920004395A (ko) 수소화된 라파마이신 유도체
BR9509720A (pt) Processo para a preparação de pequenas partículas compreendendo um composto orgânico cuja solubilidade é maior em um primerio solvente miscível em água que em um segundo solvente que é aquoso e uso das pequenas partículas
KR900700094A (ko) 지방산과 모노글리세라이드의 항비루스 및 항세균 활성
ATE300298T1 (de) Behandlung von leukocyten durch photopheresis
ATE137979T1 (de) Transdermische vorrichtung
KR950031059A (ko) 골다공증 치료용 약제학적 조성물
ATE63220T1 (de) Transdermal resorbierbare, wasserhaltige zubereitungen von arylpropionsaeurederivaten und verfahren zur herstellung derselben.
DE59407927D1 (de) Verfahren zur herstellung von wasserlöslichen polymerdispersionen mit hohem polymeranteil
DE69019533T2 (de) Behandlung von hiv-infizierungen und nützliche verbindungen dafür.
KR970061355A (ko) 올레핀 중합용 고체촉매성분, 그 제조방법 및 폴리올레핀의 제조방법
KR970061246A (ko) 테스토스테론을 증가시키기 위한 약학 조성물
WO1993014767A3 (en) Pharmaceutical preparation based on rhamnolipid against dermatological diseases, e.g. papilloma virus infections
KR950016760A (ko) 치질 치료제
DE69828615D1 (de) Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten
US4128632A (en) Solubilization of Rafoxanide
CA1281451C (fr) Copolymeres a blocs et un procede pour leur preparation
KR880007068A (ko) 13-시스 레티노산의 용도
KR970061248A (ko) 알츠하이머병 치료용 1, 1, 2-트리페닐부트-1-엔 유도체
KR970704442A (ko) 일시적인 병소 허혈에 의해 유발된 재관류 손상을 치료하기 위한 (S)-아데노실-L-메티오닌(SAMe) 및 그의 생리학상 적합한 염의 용도(Use of (S)-Adenosy-L-Methionine(SAMe) and lts Physiologically Compatible Salts for Treating Reperfusion Damage Triggered by Temporary Focal lschaemia)
KR910004186A (ko) 제약학적 배합물
KR890017363A (ko) 스트로빌루린 유도체, 이들의 제법 및 용도
KR880001630A (ko) 5-플루오로우라실 유도체 및 그의 용도

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050315

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee